ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

China's quest for mRNA vaccine hits stumbling block in omicron

Limited effectiveness of conventional shots puts 'zero-COVID' policy at risk

A medical worker walks past a sign at a coronavirus vaccination site in Beijing.   © Reuters

DALIAN, China -- China continues to struggle in developing a homegrown mRNA vaccine against COVID-19, with its front-runner failing to reach the market by the end of last year as hoped and now showing disappointing results against the highly infectious omicron variant.

The messenger RNA-based ARCoV vaccine candidate developed by Abogen Biosciences, Walvax Biotechnology and the Academy of Military Medical Sciences, now in Phase 3 clinical trials, encountered a snag shown in a paper published last month in the journal Cell Research.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more